Mutant IDH1 and thrombosis in gliomas

Dusten Unruh, Steven R. Schwarze, Laith Khoury, Cheddhi Thomas, Meijing Wu, Li Chen, Rui Chen, Yinxing Liu, Margaret A. Schwartz, Christina Amidei, Priya Kumthekar, Carolina G. Benjamin, Kristine Song, Caleb Dawson, Joanne M. Rispoli, Girish Fatterpekar, John G. Golfinos, Douglas Kondziolka, Matthias Karajannis, Donato PacioneDavid Zagzag, Thomas McIntyre, Matija Snuderl, Craig Horbinski*

*Corresponding author for this work

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

Mutant isocitrate dehydrogenase 1 (IDH1) is common in gliomas, and produces D-2-hydroxyglutarate (D-2-HG). The full effects of IDH1 mutations on glioma biology and tumor microenvironment are unknown. We analyzed a discovery cohort of 169 World Health Organization (WHO) grade II–IV gliomas, followed by a validation cohort of 148 cases, for IDH1 mutations, intratumoral microthrombi, and venous thromboemboli (VTE). 430 gliomas from The Cancer Genome Atlas were analyzed for mRNAs associated with coagulation, and 95 gliomas in a tissue microarray were assessed for tissue factor (TF) protein. In vitro and in vivo assays evaluated platelet aggregation and clotting time in the presence of mutant IDH1 or D-2-HG. VTE occurred in 26–30 % of patients with wild-type IDH1 gliomas, but not in patients with mutant IDH1 gliomas (0 %). IDH1 mutation status was the most powerful predictive marker for VTE, independent of variables such as GBM diagnosis and prolonged hospital stay. Microthrombi were far less common within mutant IDH1 gliomas regardless of WHO grade (85–90 % in wild-type versus 2–6 % in mutant), and were an independent predictor of IDH1 wild-type status. Among all 35 coagulation-associated genes, F3 mRNA, encoding TF, showed the strongest inverse relationship with IDH1 mutations. Mutant IDH1 gliomas had F3 gene promoter hypermethylation, with lower TF protein expression. D-2-HG rapidly inhibited platelet aggregation and blood clotting via a novel calcium-dependent, methylation-independent mechanism. Mutant IDH1 glioma engraftment in mice significantly prolonged bleeding time. Our data suggest that mutant IDH1 has potent antithrombotic activity within gliomas and throughout the peripheral circulation. These findings have implications for the pathologic evaluation of gliomas, the effect of altered isocitrate metabolism on tumor microenvironment, and risk assessment of glioma patients for VTE.

Original languageEnglish (US)
Pages (from-to)917-930
Number of pages14
JournalActa Neuropathologica
Volume132
Issue number6
DOIs
StatePublished - Dec 1 2016

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Mutant IDH1 and thrombosis in gliomas'. Together they form a unique fingerprint.

  • Cite this

    Unruh, D., Schwarze, S. R., Khoury, L., Thomas, C., Wu, M., Chen, L., Chen, R., Liu, Y., Schwartz, M. A., Amidei, C., Kumthekar, P., Benjamin, C. G., Song, K., Dawson, C., Rispoli, J. M., Fatterpekar, G., Golfinos, J. G., Kondziolka, D., Karajannis, M., ... Horbinski, C. (2016). Mutant IDH1 and thrombosis in gliomas. Acta Neuropathologica, 132(6), 917-930. https://doi.org/10.1007/s00401-016-1620-7